Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Eugene J. Sullivan"'
Autor:
David Cipolla, Jimin Zhang, Brice Korkmaz, James D. Chalmers, Jessica Basso, Daniel Lasala, Carlos Fernandez, Ariel Teper, Kevin C. Mange, Walter R. Perkins, Eugene J. Sullivan
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG
Externí odkaz:
https://doaj.org/article/85f654da54af4f9a8406df384ca1cca2
Autor:
Helena Gauani, Thomas Baker, Zhili Li, Vladimir S. Malinin, Walter R. Perkins, Eugene J. Sullivan, David Cipolla
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 934 (2023)
Treprostinil palmitil (TP), a prodrug of treprostinil, is being developed as an inhalation powder (TPIP) for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD). In
Externí odkaz:
https://doaj.org/article/901785b5f5b0470397f70a9f2a5e4176
Autor:
Walter Perkins, Richard W. Chapman, Vladimir Malinin, Michel R. Corboz, Eugene J. Sullivan, Zhili Li, David Cipolla, Adam J. Plaunt, Andy Stautberg, Donna M. Konicek, Carlos Fernandez
Publikováno v:
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research, Vol 7, Iss 1 (2021)
article-version (VoR) Version of Record
ERJ Open Research, Vol 7, Iss 1 (2021)
Cough is induced by inhaled prostacyclin analogues including treprostinil (TRE), and, at higher doses, treprostinil palmitil (TP), a prodrug of TRE. In this report, we have investigated mechanisms involved in TRE- and TP-induced cough, using a dry po
Autor:
Mark L. Metersky, Eugene J. Sullivan, Michael R. Loebinger, Charles L. Daley, Francesco Blasi, Jun Zou, James D. Chalmers, Oriol Sibila, Charles S. Haworth, Kevin C. Mange, Anne E. O'Donnell, Carlos Fernandez
Publikováno v:
Respiratory infections.
Background: Neutrophil elastase (NE) activity is increased in bronchiectasis and correlated with exacerbations. Brensocatib is an oral, selective, reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases and r
Autor:
Kevin K. Brown, Yoshikazu Inoue, Karen Smith, Kevin C. Wilson, Angelo M. Taveira-Da Silva, Steven A. Sahn, Gregory P. Downey, Simon R. Johnson, Vincent Cottin, Kuniaki Seyama, Nishant Gupta, MeiLan K. Han, Jeffrey T. Chapman, Eugene J. Sullivan, Jan Brozek, Lisa R. Young, Elizabeth P. Henske, Jeanine D'Armiento, Joel Moss, Geraldine R. Finlay, John J. Bissler, Cristopher A. Meyer, Francis X. McCormack, Robert M. Kotloff, Wendy K. Steagall, Thomas V. Colby, Jay H. Ryu, Charlie Strange, Jean F. Cordier, Kathryn A. Wikenheiser-Brokamp, Brent W. Kinder, Connie G. Glasgow
Background: Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM.Methods: Systematic reviews were performed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3747eb67c592ce58b0178884bf638418
https://europepmc.org/articles/PMC5803656/
https://europepmc.org/articles/PMC5803656/
Autor:
David Han, Carlos Fernandez, Danlin Xu, Chris Rubino, Mona Darwish, Walter Perkins, Eugene J. Sullivan
Publikováno v:
4.3 Pulmonary Circulation and Pulmonary Vascular Diseases.
Background: Inhaled treprostinil (TRE [Tyvaso ® ]) is a QID vasodilator indicated for pulmonary arterial hypertension (PAH). C16TR for Inhalation (INS1009) is a lipid nanoparticle formulation of treprostinil prodrug (hexadecyltreprostinil), under de
Autor:
Alan F. Barker, Hye-Seung Lee, James M. Stocks, Jeffrey P. Krischer, Mark L. Brantly, Kevin K. Brown, Lisa R. Young, Charlie Strange, Yoshikazu Inoue, Eugene J. Sullivan, Jeffrey T. Chapman, Joseph P. Lynch, Gregory P. Downey, Francis X. McCormack, Angelo M. Taveira-DaSilva, Brent W. Kinder, Marsha M. Cohen, Lianne G. Singer, Koh Nakata, Joel Moss, Roy T. McKay, Bruce C. Trapnell, Thomas V. Colby, Leslie L. Korbee, Hilary J. Goldberg
Publikováno v:
New England Journal of Medicine. 364:1595-1606
Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also ca
Autor:
Stacey M. Pollock-BarZiv, Eugene J. Sullivan, Gregory P. Downey, Francis X. McCormack, Simon R. Johnson, Marsha M. Cohen
Publikováno v:
Thorax. 62:176-180
Background and objective: The safety of air travel in patients with pneumothorax-prone pulmonary diseases, such as lymphangioleiomyomatosis (LAM), has not been studied to any great extent. A questionnaire-based evaluation of air travel in patients wi
Autor:
J. Terrill Huggins, Steven A. Sahn, Jose L. Mendez, Janet R. Maurer, Francis X. McCormack, Eugene J. Sullivan, Khalid F. Almoosa, Jay H. Ryu, Lisa R. Young
Publikováno v:
Chest. 129:1274-1281
Study objectives Pneumothorax is a common complication of lymphangioleiomyomatosis (LAM), and the optimal approach to its treatment and prevention is unknown. Chemical or surgical pleurodesis are often required to prevent recurrence. However, their e
Autor:
Gary S. Hoffman, Eugene J. Sullivan, Alexandra Villa-Forte, John L. Niles, Dimitrios Vassilopoulos, Peter A. Merkel, Alejandro C. Arroliga
Publikováno v:
Arthritis & Rheumatism. 49:151-155
Objective To determine the prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with diseases that may mimic systemic vasculitides, such as severe multiorgan dysfunction (MOD) and parenchymal pulmonary disorders. Methods We conducte